- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Aleafia Health Begins Exporting Medical Cannabis to Australia
The Canadian licensed producer announced its plan to send branded medical cannabis oils to its stake partner CannaPacific for distribution in the Australian medical cannabis market.
After obtaining its necessary cannabis exporting licenses, a Canadian producer will begin shipping medical marijuana oils to Australia.
On Tuesday (July 2) Aleafia Health (TSX:ALEF,OTCQX:ALEAF) announced that starting in August 2019 it will begin shipping its own branded medical cannabis oils to CannaPacific, its Australia-based partner, for distribution in the Australian market.
Aleafia Health owns a 10 percent stake in the Macleay Valley-based licensed producer.
As part of the new permit from Health Canada, the cannabis producer can also export medical cannabis extract products such as drops and sprays.
“We continue to prove the international viability of our highly differentiated cannabis health and wellness ecosystem with products, clinic operations, education and distribution,” Julian Fantino, Aleafia Health Chairman, said in the press release.
“With among the largest cultivation and extraction footprints in Canada coming online, we will continue to look to new international markets,” Fantino added.
Joshua Dennis, CEO of CannaPacific, said in a statement that the export license represented a significant milestone for the rapidly accelerating partnership between the two cannabis firms.
In a report published in 2018, New Frontier Data indicated that, while Australia represents one of the biggest cannabis markets in terms of revenues for the region, the medical space there is still in its infancy.
The research firm projected that the Australian medical base could grow to 330,000 patients by 2025, which would represent 1.2 percent of the country’s total population.
A projection from Statista places the value of the Australian medical cannabis market at AU$1.2 billion by 2024, up from AU$17.7 million in 2018.
In 2018, Health Canada said exports of medical cannabis product grew to 1,460 kilograms for dried flower and 920 liters of cannabis oil, according to a report from Marijuana Business Daily.
So far in 2019, the exporting of medical marijuana products from Canadian producers has continued to grow. Health Canada reported that 340 kilograms of dried flower and 195 litres of cannabis oil were exported during the first quarter of the year.
Aleafia Health confirmed its investment in CannaPacific in November 2018. At the time, Dennis said the synergy between the two marijuana firms would capitalize on the emerging Australian medical market. The transaction closed in January 2019.
As part of its most recent quarterly results, the Canadian firm reported a net loss of C$20.2 million for Q1 2019, mainly attributed to a one time payment from the closing transaction for acquiring its fellow marijuana producer Emblem.
As of 3:49 p.m. EDT on Tuesday, shares of the Canadian cannabis producer rose just over 3 percent for a price per share of C$1.36. Aleafia Health reached the Toronto Stock Exchange in March 2019. The Toronto-based company does not have an Australian Stock Exchange listing.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
2024 Life Science Outlook Report
Get the trends and expert predictions you need to stay ahead of the markets.
Download your outlook report today.
Learn About Exciting Investing Opportunities in the Life Science Sector
Your Newsletter Preferences
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.